Joy Allen, APRN
Family · Centre, ALNPI 1023663150
Payments from drug & device makers
Across 276 payments — averaging $16.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$598
- Boehringer Ingelheim$509
- AstraZeneca$435
- Otsuka America Pharmaceutical, Inc.$435
- AbbVie$432
- Bayer$255
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,440100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 51 | $598 |
| Boehringer Ingelheim | 28 | $509 |
| AstraZeneca | 22 | $435 |
| Otsuka America Pharmaceutical, Inc. | 20 | $435 |
| AbbVie | 31 | $432 |
| Bayer | 15 | $255 |
| Pfizer | 14 | $227 |
| Lilly USA, LLC | 15 | $226 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $162 |
| Dexcom, Inc. | 7 | $115 |
| Novo Nordisk | 7 | $106 |
| Novartis | 7 | $98 |
| Merck | 6 | $96 |
| Exact Sciences | 4 | $71 |
| Amgen | 4 | $65 |
| Xeris Pharmaceuticals, Inc. | 3 | $63 |
| Sanofi-aventis U.S. LLC | 3 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $41 |
| Phathom Pharmaceuticals, Inc. | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 3 | $39 |
| Astellas Pharma US Inc | 1 | $34 |
| Boston Scientific | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Philips North America LLC | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Vertex | 1 | $18 |
| Antares Pharma, Inc. | 1 | $16 |
| Edwards Lifesciences | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Adlon Therapeutics L.p. | 1 | $11 |
| Corium, LLC | 1 | $7 |
How this compares
$4,440 in reported general payments places this provider in the 85th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 17 | $24,014 |
| TrintellixVortioxetine Hydrobromide | 21 | $10,126 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $10,053 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 13 | $7,721 |
| EliquisApixaban | 12 | $6,489 |
| LantusInsulin Glargine,hum.Rec.Anlog | 13 | $5,682 |
| Potassium Chloride | 62 | $2,597 |
| Losartan Potassium | 113 | $1,396 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $1,278 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 48 | $1,157 |
| Cefdinir | 82 | $1,152 |
| Atorvastatin Calcium | 70 | $938 |
| Duloxetine Hcl | 11 | $824 |
| Sucralfate | 17 | $816 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 15 | $784 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $226 | $24,01417 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $47 | $15,73425 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $41 | $10,12621 claims |
| Boehringer IngelheimTrijardy Xr | $509 | $7,72113 claims |
| PfizerEliquis | $227 | $6,48912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,415 family providers in Alabama.
Other family in Centre
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.